Results for tag: "Urticaria Pigmentosa Drug"

Urticaria Pigmentosa (UP) is a rare skin disorder characterized by recurrent episodes of red or brown patches, hives, and itching. It is caused by an abnormal accumulation of mast cells in the skin. Treatment of UP is mainly symptomatic and includes antihistamines, topical steroids, and phototherapy. Immune disorders drugs are used to treat UP, as they can reduce the number of mast cells and reduce inflammation. Immune disorders drugs used to treat UP include monoclonal antibodies, such as omalizumab, and small molecule inhibitors, such as midostaurin. Omalizumab is a humanized monoclonal antibody that binds to IgE and reduces the number of mast cells. Midostaurin is a small molecule inhibitor that blocks the activity of the enzyme tyrosine kinase, which is involved in the production of mast cells. The Urticaria Pigmentosa Drug market is a rapidly growing market, driven by the increasing prevalence of UP and the development of new treatments. Companies in the market include Novartis, Pfizer, and Eli Lilly. Show Less Read more